NASDAQ: TOI
Oncology Institute Inc Stock

$2.16+0.22 (+11.34%)
Updated Apr 17, 2025
TOI Price
$2.16
Fair Value Price
-$0.05
Market Cap
$163.63M
52 Week Low
$0.13
52 Week High
$2.35
P/E
0x
P/B
45.59x
P/S
0.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$393.41M
Earnings
-$64.66M
Gross Margin
13.7%
Operating Margin
-14.53%
Profit Margin
-16.4%
Debt to Equity
47.12
Operating Cash Flow
-$27M
Beta
0.83
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

TOI Overview

The Oncology Institute Incorporated is an oncology company that provides physician services, in-house infusion and dispensary services, clinical trial services, radiation treatment services, outpatient stem cell transplants and transfusions programs, and patient support. The company also manages clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. through 67 clinics. The Oncology Institute was founded in 2007 and is based in Cerritos, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TOI's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Care Facility

Industry Rating
B
TOI
Ranked
#33 of 42

Top Ranked Stocks in Industry

View Top Medical Care Facility Stocks

Be the first to know about important TOI news, forecast changes, insider trades & much more!

TOI News

Overview

Due Diligence Score

Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TOI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TOI ($2.16) is overvalued by 4,367.85% relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TOI ($2.16) is not significantly undervalued (4,367.85%) relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TOI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TOI due diligence checks available for Premium users.

Valuation

TOI fair value

Fair Value of TOI stock based on Discounted Cash Flow (DCF)

Price
$2.16
Fair Value
-$0.05
Undervalued by
4,367.85%
TOI ($2.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TOI ($2.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TOI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TOI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
14.77x
Market
27.98x

TOI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
45.59x
Industry
4.22x
TOI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TOI's financial health

Profit margin

Revenue
$100.3M
Net Income
-$13.2M
Profit Margin
-13.1%
TOI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TOI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$172.7M
Liabilities
$169.1M
Debt to equity
47.12
TOI's short-term assets ($112.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TOI's long-term liabilities ($116.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TOI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TOI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.2M
Investing
-$1.8M
Financing
-$164.0k
TOI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TOI vs Medical Care Facility Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TOIC$163.63M+11.34%-0.00x45.59x
JYNTC$151.90M-0.10%-17.56x8.48x
BTMDA$180.54M-0.30%36.67x-1.70x
DCGOD$216.20M-3.20%10.60x0.67x
AIRSF$99.58M+6.92%-12.14x1.26x

Oncology Institute Stock FAQ

What is Oncology Institute's quote symbol?

(NASDAQ: TOI) Oncology Institute trades on the NASDAQ under the ticker symbol TOI. Oncology Institute stock quotes can also be displayed as NASDAQ: TOI.

If you're new to stock investing, here's how to buy Oncology Institute stock.

What is the 52 week high and low for Oncology Institute (NASDAQ: TOI)?

(NASDAQ: TOI) Oncology Institute's 52-week high was $2.35, and its 52-week low was $0.13. It is currently -8.09% from its 52-week high and 1,628% from its 52-week low.

How much is Oncology Institute stock worth today?

(NASDAQ: TOI) Oncology Institute currently has 75,753,229 outstanding shares. With Oncology Institute stock trading at $2.16 per share, the total value of Oncology Institute stock (market capitalization) is $163.63M.

Oncology Institute stock was originally listed at a price of $10.20 in Mar 11, 2020. If you had invested in Oncology Institute stock at $10.20, your return over the last 5 years would have been -78.82%, for an annualized return of -26.69% (not including any dividends or dividend reinvestments).

How much is Oncology Institute's stock price per share?

(NASDAQ: TOI) Oncology Institute stock price per share is $2.16 today (as of Apr 17, 2025).

What is Oncology Institute's Market Cap?

(NASDAQ: TOI) Oncology Institute's market cap is $163.63M, as of Apr 21, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oncology Institute's market cap is calculated by multiplying TOI's current stock price of $2.16 by TOI's total outstanding shares of 75,753,229.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.